# The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

> **NCT05085561** · PHASE2 · COMPLETED · sponsor: **Recursion Pharmaceuticals Inc.** · enrollment: 62 (actual)

## Conditions studied

- Cerebral Cavernous Malformation

## Interventions

- **DRUG:** REC-994
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05085561
- **Lead sponsor:** Recursion Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-17
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05085561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05085561, "The Symptomatic Cerebral Cavernous Malformation Trial of REC-994". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05085561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*